The synergistic effects of docetaxel and adenovirus-mediated NDRG2 gene on prostate cancer cell line DU145
10.3760/cma.j.issn.1008-1372.2012.11.004
- VernacularTitle:多西紫杉醇和腺病毒介导NDRG2基因对人前列腺癌细胞株DU145的协同作用
- Author:
Lei GAO
;
Chuigong YU
;
Ruixiao LI
;
Jing ZHANG
;
Jianlin YUAN
;
Guojun WU
;
He WANG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms/pathology;
Prostatic neoplasms/drug therapy;
Cell line,tumor;
Drug synergism;
Paclitaxel/pharmacology;
Cell cycle proteins/pharmacology;
Adenoviridae;
Genetic vectors
- From:
Journal of Chinese Physician
2012;(11):1455-1458
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the antitumor activities of adenovirus-mediated NDRG2 gene (Ad-NDRG2) and docetaxel on human prostate cancer DU145 cells.Methods The protein expressions of cyclin D1,cycliu E,and NDRG2 in the cells were determined by Western blot.MTT and flow cytometry were used to observe the effects of docetaxel (10-6 mol/L,10-7 mol/L,and 10-s mol/L) and Ad-NDRG2 on prostate cancer cell line DU145 in single or synergistic administration ways for 24 and 48 hours in vitro.Male BALB/C-nu mice with DU145 prostate cancer cell lines were treated by docetaxel and Ad-NDRG2 singly or synergistically in vivo.Results After infected by adenovirus,the protein expression of NDRG2 increased,but cyclin D1 and cyclin E decreased in DU145 cells.Ad-NDRG2 inhibited the cell growth (inhibition ratio =41.8％,t =4.18,P ＜0.01),promoted apoptosis (apoptosis ratio =32.4％,x2 =11.66,P ＜0.05),changed the ratio of G2/M phase from 50.2％ to 23.6％,and reversed partially the G2/M arrest,of DU145 cells induced by 10-7 mol/L docetaxel.In vivo experiment showed that docetaxel,Ad-NDRG2,and combination of docetaxel and Ad-NDRG2 inhibited tumor growth with a inhibition rate of 30.7％,28.2％,and 55.8％,respectively.The coefficient of drug interaction (CDI) of docetaxel and Ad-NDRG2 was 0.89.Conclusions Ad-NDRG2 can enhance the growth suppression and apoptosis induced by docetaxel in synergistic way in vitro and in vivo.It demonstrated the great potential of Ad-NDRG2 in the treatment of androgen-independent prostate carcinoma.
